Drugs / Pembrolizumab/Quavonlimab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04626518 | Dec 2020 → Jul 2026 overdue | clear cell renal carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pembrolizumab/Quavonlimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04626518 ↗ |
| Route | Intravenous | “Administered via IV infusion” NCT04626518 ↗ |